Rebecca Young

Oct 22, 2024 | onlinelibrary.wiley.com | Veraprapas Kittipibul |Robert J. Mentz |Rebecca Young |Javed Butler

Introduction The vericiguat global study in subjects with heart failure with reduced ejection fraction (VICTORIA) trial demonstrated a 10% relative and 4.2 events/100 patient-years absolute risk reduction in a composite of heart failure (HF) hospitalization (HFH) or cardiovascular death relative to placebo in patients with high-risk HF.1 Differences in patient risk profiles add complexity to comparing the relative efficacy of vericiguat with other approved contemporary HF therapies.2 Thus, we...